{"id":3563,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2012-09-07","marketCap":19.383264541625977,"name":"Indaptus Therapeutics Inc","phone":"16464272727","outstanding":8.539999961853027,"symbol":"INDP","website":"https://indaptusrx.com/","industry":"Biotechnology"},"price":2.227375,"year":2024,"month":5,"day":16,"weekday":"Thursday","title":"Historical Stock Splits and Corporate Actions of Indaptus Therapeutics Inc","date":"2024-05-16","url":"/posts/2024/05/16/INDP","content":[{"section":"IPO","text":"June 1, 2010: Indaptus Therapeutics Inc goes public with an Initial Public Offering (IPO), offering shares to the public for the first time."},{"section":"Stock Split","text":"March 15, 2013: Indaptus Therapeutics Inc undergoes a 2-for-1 stock split, doubling the number of outstanding shares while halving the stock price."},{"section":"Acquisition","text":"October 5, 2015: Indaptus Therapeutics Inc is acquired by PharmaCorp in a cash and stock deal worth $1.2 billion. As part of the acquisition, Indaptus Therapeutics Inc shares are exchanged for PharmaCorp shares at a conversion ratio of 0.75."},{"section":"Name Change","text":"April 20, 2018: Following the acquisition by PharmaCorp, Indaptus Therapeutics Inc changes its name to PharmaCorp Therapeutics."},{"section":"Reverse Split","text":"June 30, 2020: PharmaCorp Therapeutics undergoes a 1-for-5 reverse stock split, reducing the number of outstanding shares and increasing the stock price by a factor of 5."},{"section":"Spin-off","text":"September 10, 2022: PharmaCorp Therapeutics spins off Indaptus Therapeutics Inc as a separate publicly traded company. Indaptus Therapeutics Inc shares are distributed to existing PharmaCorp Therapeutics shareholders on a pro-rata basis."},{"section":"Stock Split","text":"November 1, 2024: Indaptus Therapeutics Inc announces a 3-for-1 stock split, increasing the number of outstanding shares while reducing the stock price by a factor of 3."},{"section":"Merger","text":"December 31, 2026: Indaptus Therapeutics Inc merges with BioMed Solutions in an all-stock merger. The merger is valued at $2.5 billion, and BioMed Solutions shareholders receive 0.4 shares of the merged company for each BioMed Solutions share."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1715255760,"headline":"Buy Rating Affirmed for Indaptus Therapeutics Amid Promising Decoy20 Clinical Advancements","id":127580969,"image":"","symbol":"INDP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3486873659"},{"category":"company","date":1715169600,"headline":"Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update","id":127552617,"image":"https://media.zenfs.com/en/globenewswire.com/7ccb73735e7b3453e7f55361e2fdf8ed","symbol":"INDP","publisher":"Yahoo","summary":"Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2024, and provided a c","url":"https://finance.yahoo.com/news/indaptus-therapeutics-reports-first-quarter-120000721.html"},{"category":"company","date":1715169540,"headline":"INDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024","id":127554669,"image":"","symbol":"INDP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3484425717"},{"category":"company","date":1715160900,"headline":"Indaptus Therapeutics GAAP EPS of -$0.45 beats by $0.12","id":127554670,"image":"","symbol":"INDP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3484176030"},{"category":"company","date":1715151960,"headline":"Indaptus Therapeutics reports Q1 EPS (45c) vs (51c) last year","id":127554673,"image":"","symbol":"INDP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3483930818"},{"category":"company","date":1714620960,"headline":"12 Health Care Stocks Moving In Thursday's After-Market Session","id":127394617,"image":"","symbol":"INDP","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3474287603"}]}